ReviewCurrent hypertension reports2012
Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.
Review in Current hypertension reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Effects of Bariatric Surgery on Renal Function in Obese Patients: A Systematic Review and Meta Analysis.PloS one · 2016Pooled it
- Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.JAMA pediatrics · 2015Pooled it
- Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies.BMC nephrology · 2014Pooled it
- Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials.Drug design, development and therapy · 2017Trial
- Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.Frontiers in endocrinology · 2026Review
- Therapeutic potential of Atractylodes lancea in restoring cardio-renal function in rats with diet-induced metabolic syndrome.BMC complementary medicine and therapies · 2025Article
- Sleeve Gastrectomy and Its Impact on Insulin Resistance and Metabolic Health: A Cohort Study.Obesity surgery · 2025Article
- Effect of 8-Methyl Nonanoic Acid, a Degradation By-Product of Dihydrocapsaicin, on Energy and Glucose Homeostasis in Diet-Induced Obese Mice.Journal of experimental pharmacology · 2025Article
- The impact of metabolic component count on IgA nephropathy prognosis.Scientific reports · 2024Article
- Mapping Obesity Trends in Saudi Arabia: A Four-Year Description Study.Healthcare (Basel, Switzerland) · 2024Article
- Evaluation of Obesity-Related Physiological Changes on Pantoprazole Clearance in Children Using a Population Pharmacokinetic Approach.Journal of clinical pharmacology · 2024Article
- Metabolic health's central role in chronic kidney disease progression: a 20-year study of obesity-metabolic phenotype transitions.Scientific reports · 2024Article
- Exercise for patients with chronic kidney disease: from cells to systems to function.American journal of physiology. Renal physiology · 2024Review
- A mendelian randomization study revealing that metabolic syndrome is causally related to renal failure.Frontiers in endocrinology · 2024Article
- Selecting the Best Gastric Anatomical Place for Biopsy to DetectMedical journal of the Islamic Republic of Iran · 2024Article
- Effects of Agricultural Intensification on Mediterranean Diets: A Narrative Review.Foods (Basel, Switzerland) · 2023Review
- Association betweenFrontiers in endocrinology · 2023Article
- Machine Learning Approach for Metabolic Syndrome Diagnosis Using Explainable Data-Augmentation-Based Classification.Diagnostics (Basel, Switzerland) · 2022Article
- A Hybrid Risk Factor Evaluation Scheme for Metabolic Syndrome and Stage 3 Chronic Kidney Disease Based on Multiple Machine Learning Techniques.Healthcare (Basel, Switzerland) · 2022Article
- Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of obesity and metabolic syndrome (MetS) has increased over the past several decades and is expected to continue to increase. Although the individual components of MetS have previously been associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), until recently there were few data on the relationship between MetS itself and incident CKD and ESRD. A recent meta-analysis demonstrated an association between MetS and CKD. When pooling 10 prospective cohort studies, MetS was associated with an increased odds ratio for an estimated glomerular filtration rate (eGFR) less than 60 mL/ min per 1.73 m2 (OR, 1.55; 95% CI, 1.34-1.80). Additionally, published data suggest an association between MetS and albuminuria. Evidence suggests that lifestyle modifications such as weight reduction, reduced dietary fat intake and cholesterol, and pharmacologic treatments may reduce the burden of MetS and thus the risk for CKD, albuminuria, and ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.